Brief: Akston Biosciences And Biolexis Collaborate To Launch A Room Temperature Stable 2Nd Generation Covid-19 Vaccine In 130+ Countries
17/03/2022 13:42
March 17 (Reuters) - Strides Pharma Science Ltd SRID.NS :
* AKSTON BIOSCIENCES AND BIOLEXIS COLLABORATE TO LAUNCH A
ROOM
TEMPERATURE STABLE 2ND GENERATION COVID-19 VACCINE IN 130+
COUNTRIES
* AKSTON BIOSCIENCES - BIOLEXIS HAS IN-LICENSED AKS-452, A
ROOM
TEMPERATURE STABLE COVID-19 VACCINE DEVELOPED ON AKSTON'S
PROPRIETARY FC FUSION PROTEIN PLATFORM
Source text for Eikon: ID:nBw3H6W67a
Further company coverage: SRID.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees